🌐 EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

🧪

Trial Match

Clinical trials test new treatments — sometimes the newest options available for a disease. Find trials that are recruiting now, near you. Open one to see its eligibility rules as simple questions to go through with your doctor.

Know your stage or your test results (such as EGFR, HER2 or BRCA)? Match trials to your own profile - nothing you type is saved.

🎯 Match trials to me

30 recruiting trials

for AML, Adult

A First-in-Human, JAB-8263 in Adult Patients With Advanced Tumors NCT04686682Phase 1, Phase 21 site📍 Tianjin Jacobio Pharmaceuticals Co., Ltd. · Tests: JAB-8263, JAB-8263 A Phase Ⅰb/Ⅱ Clinical Study of Clifutinib Besylate Combined With Chemotherapy in the Treatment of Newly Diagnosed AML NCT05133882Phase 1, Phase 21 site📍 Hanzhou Sunshine Lake Pharma Co., Ltd. · Tests: Clifutinib Besylate Gemtuzumab Chemotherapy MRD Levels; Adult Untreated, de Novo, Fav Interm Risk AML NCT04168502Phase 348 sites📍 Alessandria📍 Ancona📍 Ascoli Piceno Gruppo Italiano Malattie EMatologiche dell'Adulto · Tests: Gemtuzumab Ozogamicin A Multicenter Access and Distribution Protocol for Unlicensed Cryopreserved Cord Blood Units (CBUs) NCT01351545n/a142 sites📍 Birmingham📍 Gilbert📍 Phoenix Center for International Blood and Marrow Transplant Resear… · Tests: A multicenter access and distribution protocol for unlicensed cryopreserved cord blood units (CBUs) A Telehealth Advance Care Planning Intervention NCT05875805NA1 site📍 Rochester University of Rochester · Tests: Telehealth Serious Illness Care Program, Education Control A Prospective, Multicenter, and Exploratory Study of CMGV in the Treatment of Recurrent Adult AML and MDS-EB-2/Elder AML NCT06329999NA1 site📍 Shanghai Ruijin Hospital · Tests: CMGV Eganelisib as Monotherapy and in Combination With Cytarabine in Relapsed/Refractory AML/HR-MDS and in Combination With Azacitidine in Previously Untreated HR-MDS NCT06533761Phase 112 sites📍 Duarte📍 Aurora📍 Tampa Stelexis BioSciences · Tests: Eganelisib, Eganelisib in combination with cytarabine, Eganelisib in combination with azacitidine, Azacitadine (AZA) Venetoclax Basket Trial for High Risk Hematologic Malignancies NCT05292664Phase 15 sites📍 San Francisco📍 Aurora📍 Atlanta Andrew E. Place, MD · Tests: Venetoclax, Azacitidine, Cytarabine, Methotrexate, Hydrocortisone A Multicenter RCT of "3+7" vs Venetoclax + CACAG in Newly Diagnosed Mid/High-Risk AML Patients NCT06928376Phase 21 site📍 Beijing Chinese PLA General Hospital · Tests: Azacytidine;Cytarabine;Aclacinomycin;Chidamide;Venetoclax;Granulocyte colony-stimulating factor, "3+7" Escalation of Doses of Daratumumab in Combination With Chemotherapy (Idarubicin and Cytarabine or CPX-351) in Patients of 60 Years Old or More With Adverse Risk Acute Myeloblastic Leukemia (AML) (DARALAM) NCT05749276Phase 11 site📍 Nantes Nantes University Hospital · Tests: Darzalex Study of Oral PCLX-001 in R/R Acute Myeloid Leukemia NCT06613217Phase 11 site📍 Houston Pacylex Pharmaceuticals · Tests: zelenirstat Tissue, Blood, and Body Fluid Sample Collection From Patients With Hematologic Cancer NCT01137643n/a1 site📍 Chapel Hill UNC Lineberger Comprehensive Cancer Center · Tests: biologic sample preservation procedure, cytology specimen collection procedure Comparison of VA and D/IA Induction Regimens in Elderly Fit Acute Myeloid Leukemia Patients NCT07132684Phase 31 site📍 Tianjin Institute of Hematology & Blood Diseases Hospital, China · Tests: Daunorubicin/Idarubicin, Cytarabine, Azacitidine, Venetoclax Ziftomenib + Mezigdomide in Adolesc. and Adults w/ R/R AML NCT07355335Phase 12 sites📍 Boston📍 Boston Massachusetts General Hospital · Tests: Ziftomenib, Mezigdomide Adaptive Dual-Target CAR-T Cells for Relapsed or Refractory Hematologic Malignancies NCT07523555Phase 1, Phase 21 site📍 Shenzhen Beijing Biotech · Tests: Autologous CD19/CD22 dual-target CAR-T module, Autologous CD19/CD20 dual-target CAR-T module, Autologous BCMA/CD19 dual… Study Investigating the Efficacy and Safety of the Addition of Oral-azacitidine to Salvage Treatment by Gilteritinib in Subjects ≥18 Years of Age With Relapsed/Refractory FLT3-mutated Acute Myeloid Leukemia NCT06022003Phase 220 sites📍 Amiens📍 Angers📍 Clamart French Innovative Leukemia Organisation · Tests: AzaCITIDine Oral Tablet, Xospata Personalized NK Cell Therapy in CBT NCT02727803Phase 21 site📍 Houston M.D. Anderson Cancer Center · Tests: Allogeneic Natural Killer Cell Line NK-92, Anti-Thymocyte Globulin, Busulfan, Clofarabine, Cyclophosphamide CD64 CAR T Cell Therapy in Adults With Relapsed and/or Refractory AML NCT07347418Phase 11 site📍 Aurora University of Colorado, Denver · Tests: CD64 CAR T Cells Feasibility and Safety of Donor-derived NK-cell Infusions for Leukemia Relapse Prophylaxis After Hematopoietic Stem Cell Transplantation NCT07256210Phase 21 site📍 Moscow Federal Research Institute of Pediatric Hematology, Oncolog… · Tests: Donor-derived Natural Killer Cell DEC3-VEN vs. Venetoclax-Based vs. DA Regimens in Newly Diagnosed AML NCT07712848Phase 31 site📍 Kunming The Second Affiliated Hospital of Kunming Medical University · Tests: Arm A (VEN+"2+6"DA), Arm B (DEC3-VEN), Arm C ("3+7"DA) Study Investigating the Safety of CD19 CAR-T Cells in Relapsed/Refractory AML Expressing CD19 NCT06649227Phase 11 site📍 Lille University Hospital, Lille · Tests: CAR-T cell therapy Study Evaluating the Safety and the Efficacy of Human T Lymphoid Progenitor (HTLP) Injection to Accelerate Immune Reconstitution After Umbilical Cord Blood (UCB) Transplantation in Adult Patients With Hematologic Malignancies (HTLP-ONCO) NCT04707300Phase 1, Phase 25 sites📍 Paris📍 Pessac📍 Toulouse Assistance Publique - Hôpitaux de Paris · Tests: Human T Lymphoid Progenitor (HTLP) injection Adapt NK for High Risk Myeloid Diseases as Bridge to Allo HSCT NCT07591649Phase 1, Phase 21 site📍 Minneapolis Masonic Cancer Center, University of Minnesota · Tests: AdaptNK, Fludarabine, Cyclophosphamide, IL-2 Quality of Life-Guided Transfusion in Refractory MDS or AML NCT07328191NA1 site📍 Nice Centre Hospitalier Universitaire de Nice · Tests: Red blood cell transfusions based on EQ-5D-5L questionnaire Prospective Non-interventional Study of Adult Patients With Acute Myeloid Leukemia (AML) NCT04777916n/a30 sites📍 Amiens📍 Argenteuil📍 Bobigny Acute Leukemia French Association Venetoclax in Combination With Ivosidenib and Azacitidine for Newly Diagnosed IDH1-Mutated AML NCT06611839Phase 1, Phase 21 site📍 Tianjin Institute of Hematology & Blood Diseases Hospital, China · Tests: Ivosidenib, Venetoclax, Azacitidine Testing the Addition of Venetoclax or Gemtuzumab Ozogamicin (GO) to Usual Treatment Regimen (Cytarabine and Daunorubicin, "7+3") for Core Binding Factor Acute Myeloid Leukemia (CBF-AML) to Improve Response (A MYELOMATCH Treatment Trial) NCT06917911Phase 280 sites📍 Birmingham📍 La Jolla📍 Pembroke Pines National Cancer Institute (NCI) · Tests: Biospecimen Collection, Bone Marrow Aspiration, Cytarabine, Daunorubicin Hydrochloride, Echocardiography Test A Study of Chidamide With AZA in MRD Positive AML After Transplant NCT06066905NA1 site📍 Guangzhou Guangdong Provincial People's Hospital · Tests: chidamide and azacitidine Study Comparing the Efficacy of 2 RIC Regimens (Clofarabine vs Fludarabine) in Adults With AML Eligible to Allo-SCT NCT05917405Phase 223 sites📍 Nantes📍 Amiens📍 Angers Nantes University Hospital · Tests: Fludarabine, Busulfan, ATG, Clofarabine Pharmacokinetic Study of Venetoclax Tablets Crushed and Dissolved Into a Solution NCT06131801n/a6 sites📍 Aurora📍 Atlanta📍 Cincinnati Children's Hospital Medical Center, Cincinnati · Tests: 1. Drug: The Venetoclax PK study is collecting bodily fluid samples (ie., whole blood and optional cerebrospinal fluid)…
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy